|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
Q1 FY2022
As of Jun 30, 2021
|
Q4 FY2021
As of Mar 31, 2021
|
Q3 FY2021
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Equipment: | ||||||||||||||||||||
| Furniture, fixtures and equipment, at cost | ||||||||||||||||||||
| Accumulated depreciation | ||||||||||||||||||||
| Equipment, net | ||||||||||||||||||||
| Right of use asset | ||||||||||||||||||||
| Patents, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Line of credit | ||||||||||||||||||||
| Secured notes | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Deferred Revenue | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Accrued lease liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities: | ||||||||||||||||||||
| Secured notes | ||||||||||||||||||||
| Accrued lease liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding | ||||||||||||||||||||
| Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 16,879,645 and 11,879,645 issued and outstanding at September 30, 2025, and March 31, 2025, respectively | ||||||||||||||||||||
| Accumulated (deficit) | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
Loading...
